TIGIT+ B Cells in Autoimmunity: Insights from Research
This systematic review discusses the role of TIGIT+ B cells in immune regulation and their proposed involvement in autoimmune diseases, particularly multiple sclerosis and type 1 diabetes. The review suggests these cells may help regulate inflammation and disease progression through their interactions with other immune cells.
- Tags
- #Other
- Most relevant to
- —
- Human efficacy
- Not yet assessed
- Mechanism
- Not yet assessed
- Evidence strength
- Not yet assessed
- Outcome
- Not yet assessed
Why it matters
Understanding the role of TIGIT+ B cells could inform future research on autoimmunity and help identify potential therapeutic targets for diseases like multiple sclerosis and type 1 diabetes.
What this does not prove
The evidence for TIGIT+ B cells in other conditions, such as systemic lupus erythematosus and rheumatoid arthritis, is less direct and mostly inferred from other studies, limiting its applicability.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Systematic review
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not applicable
- Relevant MS type
- Not reported
- Publication date
- 2026-09-29
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Other
Original sources
- Primary evidenceTIGIT+ B cells: emerging immunoregulatory players in autoimmunity and transplantation tolerance with therapeutic potential. ↗DOI: 10.3389/fimmu.2026.1943517
Supporting passages (7)
study designThis review summarizes the biology, phenotype, and proposed functions of TIGIT+ B cells.
peer reviewedJournal: Frontiers in immunology
primary endpoint metThis review summarizes the biology, phenotype, and proposed functions of TIGIT+ B cells.
research categoriesIt also discusses emerging insights into their roles in autoimmunity and transplantation tolerance by explicitly distinguishing direct experimental findings from broader TIGIT-related data, and finally explores therapeutic strategies targeting TIGIT signaling, highlighting key challenges and opportunities for future research and clinical applications.
publication datePublication date: 2026-09-29
findingsThe strongest direct evidence for a role of TIGIT+ B cells in autoimmune pathogenesis exists in multiple sclerosis and type 1 diabetes, where these cells display regulatory activity and may help limit disease progression.
limitationsIn contrast, evidence in systemic lupus erythematosus, rheumatoid arthritis, and transplantation tolerance remains more limited and largely indirect, often inferred from broader regulatory B cell (Breg) biology, TIGIT studies in other immune cell types, or systemic pharmacologic interventions.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.